文献速递胃肠外科围术期管理与 ERAS

减重手术后出院VTE预防:275843例患者出血与血栓风险平衡

Post-discharge VTE prophylaxis after bariatric surgery: balancing bleeding risk and thrombosis prevention in 275,843 patients.
PubMed 文献 · Surg Endosc · 2026-06-08

该回顾性队列研究分析2018至2025年275843例成人袖状胃切除或Roux-en-Y胃旁路术后出院VTE药物预防模式与结局。23.1%患者接受出院后预防,POD90总体VTE发生率为0.61%。阿哌沙班2.5 mg每日两次、利伐沙班10 mg每日一次和依诺肝素40 mg每日两次与较低VTE风险相关且未增加出血。

要点

  • 减重术后出院VTE药物预防使用率为23.1%,方案差异大。
  • 阿哌沙班2.5 mg bid和依诺肝素40 mg bid与匹配对照组相比90天VTE发生率更低。
  • 常用方案中未观察到出血风险显著增加。

核心结论

  • 减重术后出院VTE药物预防方案差异显著,不同方案安全性和有效性存在有意义的差别。
  • 倾向性评分匹配分析中,阿哌沙班2.5 mg每日两次和依诺肝素40 mg每日两次各自与匹配对照组相比90天VTE发生率更低,且未显著增加出血。

研究设计与样本

  • 回顾性分析国家数据库,纳入2018至2025年接受初次袖状胃切除(n=184587)或Roux-en-Y胃旁路(n=91256)的成人患者。
  • 主要结局为术后90天内的VTE和出血事件,采用多变量逻辑回归和倾向性评分匹配评估常用预防方案与结局的关联。

主要发现

  • 275843例患者中63744例(23.1%)接受出院后药物预防。
  • 出院后VTE发生率POD30为0.45%,POD90为0.61%。
  • 依诺肝素40 mg每日一次是最常处方方案(35.8%;n=22799)。
  • 多变量分析中,阿哌沙班2.5 mg每日两次(OR 0.62,95%CI 0.41-0.90)、利伐沙班10 mg每日一次(OR 0.55,95%CI 0.26-0.99)和依诺肝素40 mg每日两次(OR 0.72,95%CI 0.58-0.88)与POD90 VTE几率更低独立相关,且与无预防相比未增加出血几率。
  • 倾向性评分匹配分析中,90天VTE发生率阿哌沙班2.5 mg每日两次为0.41% vs 0.64%(p=0.050;q=0.050),依诺肝素40 mg每日两次为0.53% vs 0.75%(p=0.003)。

临床怎么用

  • 减重术后出院VTE药物预防需权衡血栓与出血风险,常用方案中阿哌沙班2.5 mg每日两次和依诺肝素40 mg每日两次与较低90天VTE发生率相关。
  • 临床选择具体药物和剂量时需结合患者个体出血风险,并注意当前证据来自回顾性研究。

局限性

  • 回顾性研究设计,存在残余混杂可能。
  • 需前瞻性随机研究确定最佳患者选择、方案选择和疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-discharge venous thromboembolism (VTE) chemoprophylaxis after metabolic and bariatric surgery is variably implemented in clinical practice, although the optimal pharmacologic agent and dosing regimen remain unclear. This study characterized national practice patterns in VTE chemoprophylaxis and evaluated the associations of commonly prescribed post-discharge prophylactic regimens with VTE and bleeding outcomes. METHODS: A retrospective analysis of a national database identified adult patients undergoing primary sleeve gastrectomy (n = 184,587) or Roux-en-Y gastric bypass (n = 91,256) between 2018 and 2025. The primary outcomes were VTE and bleeding events through 90 postoperative days (POD). Multivariable logistic regression and propensity score matching were used to evaluate the associations of common chemoprophylaxis regimens with VTE and bleeding. RESULTS: Among 275,843 patients undergoing metabolic and bariatric surgery, 63,744 (23.1%) received post-discharge chemoprophylaxis. Overall post-discharge VTE incidence was 0.45% at POD30 and 0.61% at POD90. Enoxaparin 40 mg once daily was the most frequently prescribed regimen (35.8%; n = 22,799). On multivariable analysis, apixaban 2.5 mg twice daily (OR 0.62, 95% CI 0.41-0.90), rivaroxaban 10 mg once daily (OR 0.55, 95% CI 0.26-0.99), and enoxaparin 40 mg twice daily (OR 0.72, 95% CI 0.58-0.88) were independently associated with lower odds of VTE through POD90 without increased odds of bleeding compared with no prophylaxis. In propensity score-matched analyses, 90-day VTE incidence was lower for apixaban 2.5 mg twice daily (0.41% vs. 0.64%; p = 0.050; q = 0.050) and enoxaparin 40 mg twice daily (0.53% vs. 0.75%; p = 0.003) compared with matched controls. CONCLUSIONS: Post-discharge VTE chemoprophylaxis after metabolic and bariatric surgery varies substantially, with meaningful differences in safety and effectiveness across regimens. In propensity score-matched analyses, apixaban 2.5 mg twice daily and enoxaparin 40 mg twice daily were each associated with lower 90-day VTE incidence compared with matched controls, without significant increase in bleeding. Prospective randomized studies are needed to define optimal patient selection, regimen selection, and therapy duration.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Gillikin AP, Rabinovich EP, Barajas-Gamboa JS, et al. Post-discharge VTE prophylaxis after bariatric surgery: balancing bleeding risk and thrombosis prevention in 275,843 patients. Surg Endosc. 2026. PMID: 42260174. doi:10.1007/s00464-026-12954-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。